

This is the peer-reviewed, manuscript version of the following article:

Suiter, E. J., Packer, R. M. A. and Volk, H. A. (2016) 'Comparing the effects of first-line antiepileptic drugs on the gait of dogs with idiopathic epilepsy', *Veterinary Record*.

The final version is available online via <http://dx.doi.org/10.1136/vr.103736>.

The full details of the published version of the article are as follows:

TITLE: Comparing the effects of first-line antiepileptic drugs on the gait of dogs with idiopathic epilepsy

AUTHORS: Suiter, E. J., Packer, R. M. A. and Volk, H. A

JOURNAL TITLE: *Veterinary Record*

PUBLISHER: BMJ Publishing Group

PUBLICATION DATE: 14 June 2016 (online)

DOI: 10.1136/vr.103736

**Comparing the effects of first line antiepileptic drugs on the gait of dogs with idiopathic epilepsy**

Emma J Suiter, Rowena MA Packer, Holger A Volk\*

Department of Clinical Science and Services, Royal Veterinary College, Hatfield,  
Hertfordshire, UK

\* Corresponding author: Holger A Volk, Department of Clinical Science and Services, Royal  
Veterinary College, Hatfield, UK

[hvolk@rvc.ac.uk](mailto:hvolk@rvc.ac.uk)

1 **Abstract**

2

3 Idiopathic epilepsy (IE) is a common chronic neurological disease of the dog. Previous studies  
4 of anti-epileptic drug (AED) treatment have indicated that acceptable AED adverse effects are  
5 as important to owners as reductions in seizure frequency. AEDs in both dogs and humans are  
6 frequently associated with the adverse effect ataxia. The aim of this study was to compare  
7 ataxia levels in dogs with IE treated chronically with phenobarbitone or imepitoin, the two  
8 currently available first-line AED treatments. The gait of six imepitoin-treated dogs, eight  
9 phenobarbitone-treated dogs and ten age-matched healthy control dogs were compared. Fifty  
10 strides from a walking gait were analysed for each dog, quantifying ataxia via the variability  
11 in six established gait parameters. Three variables differed significantly between groups: lateral  
12 distance between (i) pelvic paw placements, (ii) thoracic paw placements and (iii) stance time,  
13 which were significantly more variable in the phenobarbitone-treated dogs than imepitoin-  
14 treated or control dogs. These results indicate that dogs treated with phenobarbitone experience  
15 increased ataxia compared to controls and imepitoin-treated dogs. Conversely, there was no  
16 difference between imepitoin-treated dogs and controls. These results along with further  
17 research are needed to quantify AEDs adverse effects, to help vets and owners make more  
18 informed drug-choices.

19

20

21

22

23

24

25

---

**Abbreviation**

---

<b>AED</b>	Anti-epileptic drug
<b>BID</b>	Twice a day
<b>CNS</b>	Central Nervous System
<b>CMSM</b>	Chiari like malformation and Syringomyelia
<b>CV</b>	Coefficient of Variation
<b>IE</b>	Idiopathic Epilepsy
<b>MRI</b>	Magnetic Resonance Imaging
<b>PB</b>	Phenobarbitone
<b>RVC</b>	Royal Veterinary College
<b>QOL</b>	Quality of Life

---

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

## 43 **Introduction**

44

45 Idiopathic epilepsy (IE) is a brain disease characterised by recurrent seizures that is diagnosed  
46 by exclusion of identifiable structural and metabolic causes, and can be of genetic aetiology  
47 (Berendt and others 2015; Thomas 2000). The prevalence of IE within the UK dog population  
48 is reported at 0.62% (Kearsley-Fleet and others 2013), and raw data from the Royal Veterinary  
49 Colleges VetCompass records found that seizures are the third most reported nervous system  
50 presentation in dogs (VetCompass 2016). While prevalence alone indicates the importance of  
51 this disease, IE also has potentially large welfare implications for the affected dog (Packer and  
52 Volk 2015a) and can be distressing for owners to witness and manage (Lord and Podell 1999;  
53 Wessmann and others 2014).

54

55 There are several antiepileptic drugs (AED) available for dogs with IE as monotherapies or  
56 adjunct polytherapies. Phenobarbitone (PB) and imepitoin are two licensed AEDs in the UK,  
57 Australia and most countries in Europe. Both drugs have been demonstrated to have good  
58 efficacy when used as a first-line treatment for dogs with IE (Charalambous and others 2014).  
59 PB has been shown to effectively reduce seizure frequency, but has also been associated with  
60 adverse effects such as sedation, polyphagia, polyuria, polydipsia and ataxia (Tipold and others  
61 2015). Imepitoin has some potential benefits over PB as it has fewer reported adverse effects  
62 and does not require serum level measurements due to its high therapeutic index (Rundfeldt  
63 and Löscher 2014; Tipold and others 2015).

64

65 A study investigating owners' perception of the adequacy of seizure control, showed that  
66 quality of life (QoL) and acceptable adverse effects of AEDs were just as important to owners  
67 as a reduction in seizure frequency (Chang and others 2006). There is currently a lack of

68 objective data regarding AED adverse effect profiles (Charalambous and others 2014),  
69 hampering objective choice of AEDs based on both efficacy and adverse effect profile. As  
70 such, there is a strong need for more objective studies of the adverse effects of drugs including  
71 PB and imepitoin. One of the reported adverse effects of PB is ataxia (Tipold and others 2015),  
72 with one survey reporting ataxia in 30% of PB-treated dogs (Chang and others 2006).

73

74 Ataxia is a loss of control of limb coordination and position, which results in delayed and  
75 variable foot placements (Hamilton and others 2007). In human medicine, ataxia or a loss of  
76 balance associated with AEDs has been a focus of study due its association with falls and  
77 skeletal fractures (Fife and Sirven 2005; Gandelman-Marton and others 2006; Mattson and  
78 Gidal 2004). One study found that balance was impaired in epilepsy patients with AEDs  
79 compared to their non-AED treated siblings (Petty and others 2010). As yet, similar studies  
80 objectively assessing the impact of AEDs on gait have not yet been performed in dogs with IE.

81

82 The use of gait analysis to identify or quantify the severity of neurological gait abnormalities  
83 is often carried out using subjective scale systems, such as a 14-point numerical scale assessing  
84 the gait patterns observed (Olby and others 2001). This method is easily implemented in a  
85 clinical setting and has been used to assess the recovery of dogs post spinal surgery successfully  
86 (Olby and others 2004). There are concerns, however, with reproducibility of rating scales due  
87 to their subjective nature (Gordon-Evans and others 2009), observer bias (Arkeell and others  
88 2006) and the influence of observer experience on the results (Keegan and others 2010; Keegan  
89 and others 1998). Objective gait measurements are increasingly feasible due to the increased  
90 availability of high definition cameras and relevant computer software. For example, pelvic  
91 limb paw placement was successfully quantified in dogs with spinal cord injury using high  
92 definition motion cameras and markers (Hamilton and others 2007), with increased variability

93 in lateral paw position seen in dogs with spinal cord injury (Hamilton and others 2008). An  
94 alternative method using high speed recordings of dogs on treadmills revealed lateral instability  
95 and an increase in gait parameter variability in dogs with spinal cord injury (Jeffery and others  
96 2011). Most recently, a combination of using a subjective scale system and high definition  
97 filming has been used to produce continuous data sets for use in future clinical trials in dogs  
98 with spinal cord injury and ataxia, as well as simplistic gait analysis methods to better quantify  
99 ataxia (Olby and others 2014; Song and others 2016; Suiter and others 2013). By formulating  
100 a method that takes into consideration gait parameters such as stride length, lateral paw  
101 placement and step cycle, it may be possible to objectively quantify the presence and degree of  
102 ataxia in dogs being treated with AEDs.

103

104 The aim of this study was to objectively evaluate the gait of dogs with IE being treated with  
105 either PB or imepitoin as monotherapy for canine IE. It is hypothesised that the PB- or  
106 imepitoin-treated dogs will show greater variability in their gait parameters compared to a  
107 healthy control dog population. This is the first known study to quantify gait parameters in  
108 dogs receiving AED therapy, and provides important data on adverse effects.

109

## 110 **Method and Materials**

111

### 112 ***Recruitment***

113 Dogs were recruited for three separate study groups; healthy control dogs, PB-treated dogs,  
114 and imepitoin-treated dogs. Due to the variation in breed of dogs affected by IE, and the  
115 potential impact of conformation on gait, control dogs were chosen that were close in age and  
116 size to the dogs with epilepsy. Control dogs belonged to vet students and staff from the Royal  
117 Veterinary College (RVC), Hertfordshire, and IE dogs were recruited via social media and

118 from first opinion small animal vet practices. To be included in the study dogs were required  
119 to meet the following inclusion criteria:

- 120 (i) Between 6 months and 10 years of age
- 121 (ii) Confirmed by a veterinary surgeon to be free of orthopaedic disease based on  
122 clinical history
- 123 (iii) Dogs with IE were required to fit Tier I or Tier II confidence level of IE diagnosis  
124 (De Risio and others 2015). In brief, Tier I dogs had a history of two or more  
125 epileptic seizures with unremarkable inter-ictal physical and neurological  
126 examination with normal bloodwork and urinalysis. Tier II dogs had the same  
127 findings as Tier 1 with added diagnostics revealing normal brain MRI findings,  
128 unremarkable bile acids and unremarkable cerebrospinal fluid analysis.
- 129 (iv) Dogs with IE were required to have been treated with PB or imepitoin as a  
130 monotherapy for at least 2 weeks prior to the study.

131 All owners who volunteered their dogs were provided with an owner information sheet (RVC  
132 Animal Welfare and Ethics Committee reference 2015/T334) explaining the study protocol and  
133 signed a consent form to allow their dogs involvement in the study.

#### 134 ***Gait analysis***

135

136

137 Motion capture was performed in the structure and motion lab situated at the RVC and at  
138 owner's homes if they could not travel. Two digital stills cameras (Nikon 1-J1 model) capable  
139 of full high definition video capture were used. Both cameras were set up over 1m away from  
140 the walkway mat in order to capture both a front on, and lateral view of the dogs. The dogs  
141 were walked over-ground along an 8 m runway with black electrical tape marking up 0.5 x  
142 0.5m squares into a 0.5 x 5 m grid made up of black tape on a flat surface. Cameras and the  
143 runway mat were fully portable so could be taken to owners' houses if required. The mat was



144 placed on a flat and solid surface and the camera set-up was as described above. Both cameras  
145 were set to film in full high definition, pixel 1920x1080 at 60fps, shutter speed 1/1250. Owners  
146 were then asked to walk their dog at their own comfortable walking gait on the lead. Owners  
147 were advised on how best to walk their dog along the runway, ensuring the dog remained within  
148 the mat at all times during the walk. Dogs did not require any training or markers on their  
149 bodies to be filmed. If a dog transitioned into another gait (e.g. trot or pace), stopped or became  
150 distracted during a walk, the filming was aborted and the walk repeated. 50 strides were  
151 collected in order to increase the reliability and statistical power of the results, and is similar  
152 or in excess of the number of strides used in other gait studies analysing ataxia in dogs  
153 (Hamilton and others 2007; Ishihara and others 2009; Jeffery and others 2011)

154

155 Parameters measured were chosen based on parameters measured in other neurological gait  
156 studies (Hamilton and others 2007; Jeffery and others 2011; Olby and others 2014) and are  
157 summarised in Table 1. These parameters were measured post-filming using the recorded  
158 footage, assessing each dog's gait using Quintic Video Analysis Software (Quintic  
159 Consultancy Ltd, West Midlands, UK). To analyse paw placements, freeze frames were taken  
160 at points where a paw was fully on the ground. This was performed with footage from both  
161 cameras and was performed for every foot for all strides taken. Once all the frames were  
162 collected, images were opened with software 'Image J' (ImageJ 2012). Image J allowed a scale  
163 to be set for the grid, so the image coordinates (pixels) matched real life coordinates (cm) and  
164 chosen parameters were measured using the straight line tool.

165

## 166 **Statistical analysis**

167

168 Data were collated in Microsoft Excel 2010 (Microsoft Corp, Redmond, WA, US) then  
169 analysed using GraphPad Prism (Version 5, ©1992-2010 GraphPad Software, Inc.) for  
170 univariate analysis, and IBM SPSS Statistics (Version 19, Armonk, NY: IBM Corp) for  
171 multivariate analysis. For each gait parameter the mean and standard deviation was calculated,

172 along with the coefficient of variation (CV = standard deviation / mean). CV is a unit-less  
173 parameter which quantifies the spread of data relating to the variability of a parameter. A higher  
174 CV value indicates more variable data. By examining only the variability of the individual's  
175 gait, and not the exact parameter measurements, differences between study subjects cannot be  
176 simply attributed to variation in size or conformation. Instead, the CV values focus on  
177 coordination consistency of the individual (Hamilton and others 2008).

178

179 CV values were checked for normality of distribution, then groups were statistically compared  
180 at the univariate level using the non-parametric Kruskal-Wallis test, with summary statistics  
181 stated as medians and 25<sup>th</sup>-75<sup>th</sup> percentiles. If the Kruskal-Wallis test discovered significant  
182 differences between the groups, a post-hoc Dunn's test was performed to determine which  
183 groups differed from each other. Linear mixed models were then created to further analyse the  
184 association between treatment group and gait parameters. The CV of gait parameters were  
185 included as outcome measures, with the random effect of dog ID included in all models to take  
186 into account individual variation between dogs, with the fixed effect of medication group  
187 (imepitoin, PB, or control). A p-value of less than 0.05 was considered significant in all tests.

188

## 189 **Results**

190

191 Twenty-four dogs were recruited; healthy control dogs (n=10), PB-treated dogs with IE (n=8),  
192 and imepitoin-treated dogs with IE (n=6). Details of the dogs recruited are summarised in Table  
193 2. Ages of the dogs did not significantly differ between groups.

194

### 195 *Gait analysis*

196

197 CV of two of the six gait parameters measured were found to significantly differ between  
198 groups at the univariate level, CV of pelvic paw distance and thoracic paw distance. CV of  
199 pelvic and thoracic paw distance was found to differ significantly between the following study  
200 groups, with the PB group showing a significantly higher variability in pelvic paw distance  
201 compared to the control group and imepitoin-treated group (Figure 1 and 2, and Table 3). There  
202 were, however, no significant differences between the CV of thoracic or pelvic paw distance  
203 between the control and imepitoin groups. No significant differences were found between the  
204 groups at the univariate level for the CV of step time, stance time, stride length and ipsilateral  
205 distance (Table 3).

206

207 When individual dog variation was accounted for in a linear mixed model, including dog ID as  
208 a random effect, CV of pelvic paw distance and thoracic paw distance remained significantly  
209 different between groups, with higher variability seen in the PB group compared to controls. A  
210 further association was found between CV of stance time and treatment group, with the PB  
211 group significantly more variable compared to controls (Figure 3 and Table 4).

212

213

214 **Discussion**

215

216 This study aimed to evaluate the variability of gait in dogs with IE treated with either PB or  
217 imepitoin, in order to quantify the adverse effect ataxia. To the authors' knowledge this is the  
218 first time the gait of dogs treated for IE has been objectively quantified. The method described  
219 in this study could quantify an increase in paw placement variability, as reflected in our results.  
220 Previous studies quantifying ataxia in dogs have used treadmills to maintain speed and remove  
221 variables such as direction change or handler error (Gordon-Evans and others 2009; Hamilton  
222 and others 2007, 2008; Olby and others 2014). Using trademills is not without problems, and  
223 if time is not spent habituating animals on the treadmill this can severely alter results (Clements  
224 and others 2005) and is also time and training intensive (Buchner 1994). By using the method  
225 described in this study, walking in a familiar on-lead manner on a walkway, error due to  
226 unfamiliarity and/or anxiety is reduced and is feasible for the owner and researchers to  
227 complete. Collecting data at owners' homes also had the benefit of allowing dogs to be in their  
228 familiar environments, which is expected to reduce anxiety. Anxiety in novel environments  
229 may affect gait as dogs may exhibit behaviours such as an inability to settle, seeking exit or  
230 attempting to walk closer to their owners for security. A limitation of our study design is that  
231 the analyser for the study also recruited the dogs, and therefore was not completely blinded.  
232 However, analysis of gait was temporally apart from video capture and gait parameter  
233 measurements were objective using a consistent measurement technique.

234

235 A wide variety of breeds were recruited for this study, due to epilepsy affecting many breeds  
236 (Hülsmeier and others 2015); however, this may be considered a limitation due to potentially  
237 significant variation in gait between breeds related to size, weight and conformation. To reduce  
238 this potential effect, we examined the CV of the individual dog's gait parameters rather than

239 the raw values. CV has been used to summarise the variability of foot placement during  
240 movement to quantify ataxia in people (Dubost and others 2008), dogs (Hamilton and others  
241 2008) and horses (Olsen 2015). Hamilton and others (2008) interpreted an increase in CV  
242 values for pelvic and thoracic paws distance to be related to the inability of a dog to place their  
243 feet back into the correct lateral plane due to their ataxia. As we were able to also show a  
244 significant increase in CV values for the PB treated dogs, which we expected to be ataxic, this  
245 is supportive that our method can detect ataxia. A more recent study looking into simplified  
246 gait analysis of dogs' post-spinal cord injury (Song and others 2016) found that the CV of  
247 'Base of Support' in pelvic and thoracic limbs (similar measurement to lateral distance used in  
248 this study) did not significantly differ between normal dogs and those with spinal cord injury.  
249 However, dogs with spinal cord injury typically have asymmetrical spinal lesions which can  
250 allow for compensation. In contrast, dogs treated with antiepileptic drugs are expected to have  
251 symmetrical deficits, due to an increase in the action of GABA (Podell 1998). This could be  
252 altering the proprioceptive pathways and their central processing, due to unspecific targeting  
253 within the CNS.

254

255 The results of this study indicate that being treated with PB affects the gait of dogs with IE.  
256 This is similar to previous findings in people (Fife and Sirven 2005; Gandelman-Marton and  
257 others 2006; Petty and others 2010) although not directly replicated. Dogs treated with PB were  
258 shown to have a significantly higher variability in their lateral paw placements (pelvic paw  
259 distance and thoracic paw distance) and stance, suggesting an inability to coordinate their paw  
260 positioning whilst walking when compared to the imepitoin treated dogs and control dogs. This  
261 finding supports our initial hypothesis, and provides objective support for the observation that  
262 PB causes ataxia in dogs with IE, as previously reported by owners and clinicians (Chang and  
263 others 2006; Dayrell-Hart and others 1991; Tipold and others 2015). In comparison, the

264 imepitoin-treated groups had very similar CV values to the control group. By having CV values  
265 as low as the control groups, we can assume that this is because the imepitoin treated dogs  
266 show little to no signs of ataxia. This is likely due to imepitoin's mechanism of action.  
267 Imepitoin is a partial agonist of GABA<sub>A</sub> receptors, and acts on the benzodiazepine site which  
268 only modulates the GABA effect, rather than directly activating the receptor (Tipold and others  
269 2015). By having a much lower intrinsic activity in comparison to PB, this could explain why  
270 ataxia and other adverse effects are seen less often (Rundfeldt and Löscher 2014) and why we  
271 found no difference to our control group CV values.

272

273 CV of step time was not found to differ between treatment groups in any analysis. CV of stance  
274 time variability did not differ between treatment groups in the univariate analysis. However,  
275 when the non-independence introduced by individual dog variation was accounted for in a  
276 mixed effects model, CV of stance time was significantly more variable in PB treated dogs  
277 compared to controls. Step time and stance time have been found to be significantly reduced  
278 in mice with spinal cord injury (Beare and others 2009) as well as in ataxic dogs (Gordon-  
279 Evans and others 2009). The PB treated dogs in this study did not have reduced stance time,  
280 but more variable stance time during their walking gait, which could be explained by the large  
281 variability from stride to stride. In combination with the lateral paw placement variability, we  
282 can expect that with some wide and some narrow strides, there will be varying times that the  
283 opposing paw will be kept on the ground in order to remain balanced during the walk. The  
284 other measured parameters did not show a change in variability between the three groups.  
285 Ipsilateral paw distance variability has only previously been measured in one study, where the  
286 gait of Cavalier King Charles Spaniels with Chiari-like malformation and Syringomyelia  
287 (CMSM) was studied. That study showed a significantly higher variability in ipsilateral paws  
288 distance compared to a group of similarly-sized control dogs (Suiter and others 2013). In this

289 study, PB-treated dogs did not show this, which may be explained by the diffuse effect of PB  
290 on the CNS compared to a more localised pathology seen in dogs with CMSM. Stride length  
291 variability did not differ between groups, which was unexpected as an uncoordinated gait with  
292 a combination of long and short strides may be expected due to altered balance during the walk.  
293 It is likely that to see an increase in stride length variability, the dogs would have observable  
294 ataxia, as this is what has been found in previous ataxia studies (Hamilton and others 2008;  
295 Olby and others 2014; Gordon-Evans and others 2009). The PB treated dogs in this study were  
296 not reported to have ataxia by the owners, and often it is dogs who are in the first month of PB  
297 administration that show the most ataxia (Boothe and others 2012). As our dogs were  
298 chronically treated with phenobarbitone, they have had time to adjust to the drug activity and  
299 therefore only show mild ataxia which the owners might notice anymore subjectively but can  
300 be picked up by more objective assessment techniques. As well as this, previous ataxia studies  
301 (Hamilton and others 2008; Olby and others 2014; Gordon-Evans and others 2009) have looked  
302 at localised spinal pathology rather than at a diffuse reduction in CNS activity.

303

304 The PB group had a much wider range in CV values as well as higher mean CV values. This  
305 may indicate that PB treatment affects individuals to different extents, with variation in the  
306 presence and severity of ataxia. An owner survey found that PB-treated dogs had a reported  
307 ataxia incidence of 30% (Chang and others 2006), and thus not all dogs might be affected by  
308 this adverse effect or more likely owners do not recognise the adverse-effect ataxia. As  
309 aforementioned within this study none of the owners of the IE dogs declared ataxia as a problem  
310 in their dogs' lives. Two PB treated dogs were no longer achieving fast times in agility training,  
311 however the owners were confident their dogs' QoL was not affected. Further research into  
312 how PB serum levels correlate with ataxia severity would be worthwhile and it would be  
313 interesting to understand owner's subjective thresholds for reporting ataxia in their dogs.

314 Further research is also required to compare the prevalence and severity of ataxia seen with  
315 different AEDs available to treat dogs with IE, or of different combinations of AEDs, as many  
316 IE affected dogs require more than one AED to control their seizures (Packer and others 2015b;  
317 Platt and others 2006; Schwartz-Porsche and others 1985; Thomas 2000). Quantifying AED  
318 adverse effects is an important area of study, as IE affected dogs are treated with these  
319 medications chronically due to IEs lifelong nature, and the relative rarity of remission (Packer  
320 and others 2014). This means that chronic adverse effects may have a large and lasting impact  
321 on the QoL of the treated dog and their owner. The more that is understood about AED adverse  
322 effects, which drugs they are most commonly associated with, and which dogs are most likely  
323 to be affected by them, the more vets will be able to offer a more tailored approach to IE  
324 treatment, to best suit the individual patient.

325

326

### 327 **Acknowledgements**

328

329 We would like to thank the volunteers who allowed us to film their dogs for this study, and  
330 The Kennel Club Charitable Trust for funding of this study. We would like to thank Dr. Emil  
331 Olsen for critically reviewing the manuscript. This manuscript internally approved for  
332 submission (Manuscript ID number CSS\_01175).

333

334



335 **References**

336 ARKELL, M., ARCHER, R. M., GUITIAN, F. J. & MAY, S. A. (2006) Evidence of bias affecting the  
337 interpretation of the results of local anaesthetic nerve blocks when assessing lameness in horses.  
338 *Vet Rec* 159, 346-349

339 BERENDT, M., FARQUHAR, R., MANDIGERS, P., PAKOZDY, A., BHATTI, S., DE RISIO, L., FISCHER, A.,  
340 LONG, S., MATIASEK, K., MUNANA, K., PATTERSON, E., PENDERIS, J., PLATT, S., PODELL, M.,  
341 POTSCHKA, H., PUMAROLA, M., RUSBRIDGE, C., STEIN, V., TIPOLD, A. & VOLK, H. (2015)  
342 International veterinary epilepsy task force consensus report on epilepsy definition, classification  
343 and terminology in companion animals. *BMC Vet Res* 11, 182

344 BOOTHE, D. M., DEWEY, C. & CARPENTER, D. M. (2012) Comparison of phenobarbital with bromide  
345 as a first-choice antiepileptic drug for treatment of epilepsy in dogs. *Journal of the American*  
346 *Veterinary Medical Association* 240, 1073-1083

347 BUCHNER, H. H. F., SAVELBERG, H. H. C. M., SCHAMHARDT, H. C., MERKENS, H. W., BARNEVELD, A.,  
348 (1994) Habituation of horses to treadmill locomotion. *Equine Vet J Suppl* 17, 13-15

349 CHANG, Y., MELLOR, D. J. & ANDERSON, T. J. (2006) Idiopathic epilepsy in dogs: owners'  
350 perspectives on management with phenobarbitone and/or potassium bromide. *Journal of Small*  
351 *Animal Practice* 47, 574-581

352 CHARALAMBOUS, M., BRODBELT, D. & VOLK, H. (2014) Treatment in canine epilepsy - a systematic  
353 review. *BMC Vet Res* 10, 257

354 CLEMENTS, D. N., OWEN, M. R., CARMICHAEL, S. & REID, S. W. (2005) Kinematic analysis of the gait  
355 of 10 labrador retrievers during treadmill locomotion. *Vet Rec* 156, 478-481

356 DAYRELL-HART, B., STEINBERG, S. A., VANWINKLE, T. J. & FARNBACH, G. C. (1991) Hepatotoxicity of  
357 phenobarbital in dogs: 18 cases (1985-1989). *Journal of the American Veterinary Medical Association*  
358 199, 1060-1066

359 DE RISIO, L., BHATTI, S., MUNANA, K., PENDERIS, J., STEIN, V., TIPOLD, A., BERENDT, M., FARQUHAR,  
360 R., FISCHER, A., LONG, S., MANDIGERS, P., MATIASEK, K., PACKER, R., PAKOZDY, A., PATTERSON, N.,  
361 PLATT, S., PODELL, M., POTSCHKA, H., BATLLE, M., RUSBRIDGE, C. & VOLK, H. (2015) International  
362 veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs. *BMC Vet*  
363 *Res* 11, 148

364 DUBOST, V., ANNWEILER, C., AMINIAN, K., NAJAFI, B., HERRMANN, F. R. & BEAUCHET, O. (2008)  
365 Stride-to-stride variability while enumerating animal names among healthy young adults: Result of  
366 stride velocity or effect of attention-demanding task? *Gait & Posture* 27, 138-143

367 FIFE, T. D. & SIRVEN, J. (2005) Antiepileptic drugs and their impact on balance. *Aging Health* 1, 147-  
368 155

369 GANDELMAN-MARTON, R., ARLAZOROFF, A. & DVIR, Z. (2006) Balance performance in adult  
370 epilepsy patients. *Seizure* 15, 582-589

371 GORDON-EVANS, W. J., EVANS, R. B., KNAP, K. E., HILDRETH, J. M., PINEL, C. B., IMHOFF, D. J. &  
372 CONZEMIUS, M. G. (2009) Characterization of spatiotemporal gait characteristics in clinically normal  
373 dogs and dogs with spinal cord disease. *Am J Vet Res* 70, 1444-1449

374 HAMILTON, L., FRANKLIN, R. J. & JEFFERY, N. D. (2007) Development of a universal measure of  
375 quadrupedal forelimb-hindlimb coordination using digital motion capture and computerised  
376 analysis. *BMC Neurosci* 8, 77

377 HAMILTON, L., FRANKLIN, R. J. & JEFFERY, N. D. (2008) Quantification of deficits in lateral paw  
378 positioning after spinal cord injury in dogs. *BMC Vet Res* 4, 47

379 HÜLSMEYER, V.-I., FISCHER, A., MANDIGERS, P. J. J., DERISIO, L., BERENDT, M., RUSBRIDGE, C.,  
380 BHATTI, S. F. M., PAKOZDY, A., PATTERSON, E. E., PLATT, S., PACKER, R. M. A. & VOLK, H. A. (2015)  
381 International Veterinary Epilepsy Task Force's current understanding of idiopathic epilepsy of  
382 genetic or suspected genetic origin in purebred dogs. *BMC Veterinary Research* 11, 1-28

383 IMAGEJ (2012) Image Processing and Analysis in Java. <http://rsbweb.nih.gov/ij/download.html>.  
384 Accessed 28/03/2012 Access, 2012

385 ISHIHARA, A., REED, S. M., RAJALA-SCHULTZ, P. J., ROBERTSON, J. T. & BERTONE, A. L. (2009) Use of  
386 kinetic gait analysis for detection, quantification, and differentiation of hind limb lameness and  
387 spinal ataxia in horses. *J Am Vet Med Assoc* 234, 644-651

388 JEFFERY, N. D., HAMILTON, L. & GRANGER, N. (2011) Designing clinical trials in canine spinal cord  
389 injury as a model to translate successful laboratory interventions into clinical practice. *Vet Rec* 168,  
390 102-107

391 KEARSLEY-FLEET, L., O'NEILL, D. G., VOLK, H. A., CHURCH, D. B. & BRODBELT, D. C. (2013) Prevalence  
392 and risk factors for canine epilepsy of unknown origin in the UK. *Veterinary Record* 172, 338

393 KEEGAN, K. G., DENT, E. V., WILSON, D. A., JANICEK, J., KRAMER, J., LACARRUBBA, A., WALSH, D. M.,  
394 CASSELLS, M. W., ESTHER, T. M., SCHILTZ, P., FREES, K. E., WILHITE, C. L., CLARK, J. M., POLLITT, C. C.,  
395 SHAW, R. & NORRIS, T. (2010) Repeatability of subjective evaluation of lameness in horses. *Equine*  
396 *Vet J* 42, 92-97

397 KEEGAN, K. G., WILSON, D. A., WILSON, D. J., SMITH, B., GAUGHAN, E. M., PLEASANT, R. S., LILLICH, J.  
398 D., KRAMER, J., HOWARD, R. D., BACON-MILLER, C., DAVIS, E. G., MAY, K. A., CHERAMIE, H. S.,  
399 VALENTINO, W. L. & VAN HARREVELD, P. D. (1998) Evaluation of mild lameness in horses trotting on  
400 a treadmill by clinicians and interns or residents and correlation of their assessments with kinematic  
401 gait analysis. *Am J Vet Res* 59, 1370-1377

402 LORD, L. K. & PODELL, M. (1999) Owner perception of the care of long-term phenobarbital-treated  
403 epileptic dogs. *Journal of Small Animal Practice* 40, 11-15

404 MATTSON, R. H. & GIDAL, B. E. (2004) Fractures, epilepsy, and antiepileptic drugs. *Epilepsy &*  
405 *Behavior* 5, Supplement 2, 36-40

406 OLBY, N., BLOT, S., THIBAUD, J. L., PHILLIPS, J., O'BRIEN, D. P., BURR, J., BERG, J., BROWN, T. &  
407 BREEN, M. (2004) Cerebellar cortical degeneration in adult American Staffordshire Terriers. *J Vet*  
408 *Intern Med* 18, 201-208

409 OLBY, N., LIM, J.-H., BABB, K., BACH, K., DOMARACKI, C., WILLIAMS, K., GRIFFITH, E., HARRIS, T. &  
410 MUGUET-CHANOIT, A. (2014) Gait scoring in dogs with thoracolumbar spinal cord injuries when  
411 walking on a treadmill. *BMC Vet Res* 10, 58

412 OLBY, N. J., DE RISIO, L., MUNANA, K. R., WOSAR, M. A., SKEEN, T. M., SHARP, N. J. & KEENE, B. W.  
413 (2001) Development of a functional scoring system in dogs with acute spinal cord injuries. *Am J Vet*  
414 *Res* 62, 1624-1628

415 OLSEN, E. (2015) Can Motion Capture Detect Ataxia? In American College of Veterinary Internal  
416 Medicine ACVIM Forum. Indianapolis, Cornell University

417 PACKER, R. M. A., SHIHAB, N. K., TORRES, B. B. J. & VOLK, H. A. (2014) Clinical Risk Factors  
418 Associated with Anti-Epileptic Drug Responsiveness in Canine Epilepsy. *Plos One* 9, e106026

419 PACKER, R. M. A. & VOLK, H. A. (2015a) Epilepsy beyond seizures: a review of the impact of epilepsy  
420 and its comorbidities on health-related quality of life in dogs. *Veterinary Record* 177, 306-315

421 PACKER, R. M. A., SHIHAB, N. K., TORRES, B. B. J. & VOLK, H. A. (2015b) Responses to successive anti-  
422 epileptic drugs in canine idiopathic epilepsy. *Veterinary Record*

423 PETTY, S. J., HILL, K. D., HABER, N. E., PATON, L. M., LAWRENCE, K. M., BERKOVIC, S. F., SEIBEL, M. J.,  
424 O'BRIEN, T. J. & WARK, J. D. (2010) Balance impairment in chronic antiepileptic drug users: A twin  
425 and sibling study. *Epilepsia* 51, 280-288

426 PLATT, S. R., ADAMS, V., GAROSI, L. S., ABRAMSON, C. J., PENDERIS, J., DE STEFANI, A. & MATIASEK,  
427 L. (2006) Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. *The Veterinary*  
428 *record* 159, 881-884

429 PODELL, M. (1998) Antiepileptic drug therapy. *Clinical Techniques in Small Animal Practice* 13, 185-  
430 192

431 RUNDFELDT, C. & LÖSCHER, W. (2014) The Pharmacology of Imepitoin: The First Partial  
432 Benzodiazepine Receptor Agonist Developed for the Treatment of Epilepsy. *CNS Drugs* 28, 29-43

433 SCHWARTZ-PORSCHKE, D., LÖSCHER, W. & FREY, H. H. (1985) Therapeutic efficacy of phenobarbital  
434 and primidone in canine epilepsy: a comparison. *Journal of Veterinary Pharmacology and*  
435 *Therapeutics* 8, 113-119

436 SONG, R., OLDACH, M., DA COSTA, R., MOORE, S. (2016) A Simplified Method of Walking Track  
437 Analysis to Assess Locomotion in Dogs with Acute Spinal Cord Injury. *The Veterinary Journal* 210, 61-  
438 67

439 SUITER, E. J., OLSEN, E. PFAU, T. VOLK, H. (2013) Objective Quantification of Gait Deficits in Cavalier  
440 King Charles Spaniels with Chiari-like Malformation and Syringomyelia. In *ECVIM Proceedings 25th*  
441 *Symposium*. Ed ECVIM. Ghent, Belgium. pp 1-31

442 THOMAS, W. B. (2000) Idiopathic epilepsy in dogs. *Vet Clin North Am Small Anim Pract* 30, 183-206

443 TIPOLD, A., KEEFE, T. J., LÖSCHER, W., RUNDFELDT, C. & DE VRIES, F. (2015) Clinical efficacy and  
444 safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs.  
445 *Journal of Veterinary Pharmacology and Therapeutics* 38, 160-168

446 VETCOMPASS (2016) Disease prevalence data dogs infographics, Nervous system.  
447 <http://www.rvc.ac.uk/vetcompass/learn-zone/infographics/canine>. Accessed 26/04/2016.

448 WESSMANN, A., VOLK, H. A., PARKIN, T., ORTEGA, M. & ANDERSON, T. J. (2014) Evaluation of  
449 Quality of Life in Dogs with Idiopathic Epilepsy. *Journal of Veterinary Internal Medicine* 28, 510-514

450

451

**Table 1: Descriptors for each gait parameter measured**

<b>Stride Parameter</b>	<b>Descriptor</b>
<b>Step Time</b>	Time between the toe of the paw coming off the ground and then the same paw being placed back on the ground. Measured in seconds.
<b>Stance Time</b>	Time between foot landing on the ground and then the same paw being lifted off the ground into another stride. Measured in seconds.
<b>Stride Length</b>	The distance from where the toe of the paw of interest leaves the ground and where the same foot subsequently lands during walk. Measured in cm.
<b>Ipsilateral Paw Distance</b>	The lateral distance between the thoracic limb paw placement and the ipsilateral pelvic limb paw placement during the walk. Measured in cm.
<b>Pelvic Paw Distance</b>	The distance between the placement of the left pelvic limb paw and the subsequent right pelvic limb paw placement. Measured in cm.
<b>Thoracic Paw Distance</b>	The distance between the placement of the left thoracic limb paw and the subsequent right thoracic limb paw placement. Measured in cm.

**Table 2: Signalment and clinical characteristics of dogs enrolled in this study**

Dog ID	Age	Breed	IE Tier and Diagnosis Year	Time treated/ months	Dose / mg/kg BID	Serum Levels / µg/ml
<b>Control</b>						
C1	5.5y	Northern Inuit				
C2	5y	Labrador Cross				
C3	9y	Terrier Cross				
C4	2y	Collie Cross				
C5	6y	Terrier Cross				
C6	2y	Chihuahua				
C7	6y	Jack Russell				
C8	3y	Labrador Cross				
C9	3y	Kooikerhondje				
C10	4y	Rottweiler				
<b>Mean ± SE</b>	<b>4.5±2.0</b>					
<b>Imepitoin</b>						
I1	6y	Lurcher	Tier II 2012	30	22.5	
I2	9y	Jack Russell	Tier I 2012	24	10	
I3	7y	Jack Russell	Tier I 2014	12	10	
I4	5y	Parsons Jack Russell	Tier II 2015	1	10	
I5	6m	Dogue De Bordeaux	Tier II 2015	1	30	
I6	4y	Chinese Crested	Tier I 2015	5	20	
<b>Mean ± SE</b>	<b>5.3±1.3</b>			<b>12.2±3.5</b>	<b>17.1±2.0</b>	
<b>PB</b>						
P1	4y	Northern Inuit	Tier II 2013	24	2.5	24
P2	3y	Old English Sheepdog	Tier II 2013	22	2.5	25
P3	4y	Whippet	Tier I 2014	10	2.5	21
P4	3y	Long Haired Daschund	Tier II 2013	22	1	20
P5	4y	Parsons Jack Russell	Tier II 2014	12	2.5	22.1
P6	6y	Lurcher	Tier II 2012	20	2	15.6
P7	4y	Belgian Shepherd	Tier II 2012	32	2.5	32
P8	5y	Jack Russell	Tier II 2013	15	2	28.2
<b>Mean ± SE</b>	<b>4.1±1.0</b>			<b>19±1.6</b>	<b>2.2±0.5</b>	<b>23.5±1.04</b>

SE=Standard Error of the Mean, ID=Identity, IE=Idiopathic Epilepsy, BID="bis in die" (twice daily)

**Table 3: Gait parameters compared between treatment groups.** Coefficient of Variation (CV) of thoracic and pelvic paw distance were found to differ significantly between the following study groups, with the PB group showing a significantly higher variability in thoracic and pelvic paw distance compared to the control group and imepitoin-treated group.

Groups	Step Time	Stance Time	Stride Length	Ipsilateral Distance	Pelvic Distance	Thoracic Distance
<b>N (total steps analysed)</b>	485	485	458	376	530	530
<b>Control (n=10)</b>	0.106 (0.063-0.129)	0.101 (0.071-0.127)	0.07 (0.035-0.079)	0.08 (0.043-0.088)	<b>0.168</b> <b>(0.119-0.175)</b>	<b>0.157</b> <b>(0.126-0.164)</b>
<b>Imepitoin (n=6)</b>	0.12 (0.066-0.142)	0.1 (0.068-0.131)	0.084 (0.051-0.104)	0.077 (0.048-0.086)	<b>0.125</b> <b>(0.097-0.181)</b>	<b>0.160</b> <b>(0.081-0.172)</b>
<b>PB (n=8)</b>	0.1 (0.067-0.105)	0.149 (0.101-0.207)	0.086 (0.061-0.091)	0.076 (0.053-0.100)	<b>0.299</b> <b>(0.197-0.327)*+</b>	<b>0.293</b> <b>(0.238-0.389)*+</b>


Data are presented as median (25<sup>th</sup> – 75<sup>th</sup> percentile) of CV values from all groups. Univariate comparison between the groups was carried out by a Dunn’s Multiple Comparison Test where a p value <0.05 was deemed significant (\* = significant difference to control group; + = significant difference to imepitoin group).

**Table 4: Linear mixed model investigating the effect of treatment group on gait parameters, including individual dog as a random effect.** Coefficient of Variation of stance time, pelvic paw distance and thoracic paw distance differed significantly between groups, with higher variability seen in the phenobarbitone (PB) group compared to controls.

Variable	Stance Time		Pelvic Distance		Thoracic Distance	
	CV ( $\pm$ SE)	P	CV ( $\pm$ SE)	P	CV ( $\pm$ SE)	P
<b>Intercept</b>	0.108 ( $\pm$ 0.033)	<b>0.003*</b>	0.160 ( $\pm$ 0.039)	<b>0.001*</b>	0.159 ( $\pm$ 0.055)	<b>0.008*</b>
<b>Imepitoin</b>	0.001 ( $\pm$ 0.021)	0.952	-0.016 ( $\pm$ 0.025)	0.536	-0.011 ( $\pm$ 0.036)	0.770
<b>PB</b>	0.043 ( $\pm$ 0.020)	<b>0.046*</b>	0.134 ( $\pm$ 0.024)	<b>&lt;0.001*</b>	0.168 ( $\pm$ 0.034)	<b>&lt;0.001*</b>
<b>Control</b>			<i>ref</i>			

Coefficient of Variation (CV)  $\pm$  Standard Error (SE) values from the treatment groups, using the control group for reference. \*Linear mixed model with  $p < 0.05$  deemed significant.


**Figure 1:**



**Box and whisker plots showing the comparison of pelvic paw distance Coefficient of Variation between the three study groups.** Coefficient of Variation (CV) of pelvic paw distance was found to differ significantly between the following study groups, with the Phenobarbitone group showing a significantly higher variability in thoracic and pelvic paw distance compared to the control group and imepitoin-treated group. The upper and lower percentiles (95% and 5%) are shown by the coloured boxes, with median as a solid line through each box (\* $p < 0.05$  and \*\* $p < 0.01$ ).




**Figure 2:**



**Box and whisker plots showing the comparison of thoracic paw distance coefficient of variation between the three study groups.** Coefficient of Variation (CV) of thoracic paw distance was found to differ significantly between the following study groups, with the Phenobarbitone group showing a significantly higher variability in thoracic and pelvic paw distance compared to the control group and imepitoin-treated group. The upper and lower percentiles (95% and 5%) are shown by the coloured boxes, with median as a solid line through each box (\* $p < 0.05$  and \*\* $p < 0.01$ ).

**Figure 3:**



**Box and whisker plots showing the comparison of stance time Coefficient of Variation between the three study groups.** Coefficient of Variation (CV) of stance time was found to differ significantly between the following study groups, with the Phenobarbitone group showing a significantly higher variability compared to the control group. The upper and lower percentiles (95% and 5%) are shown by the coloured boxes, with median as a solid line through each box. One asterisk (\*) represents significance of  $p < 0.05$  following a linear mixed model analysis.